Vol 5, Supp. A (2009)
suplement
Published online: 2009-04-29
Antiangiogenic treatment in patients with renal cell carcinoma
Abstract
Due to its increasing incidence, stilth course and resistance to classic pharmacotherapy, renal cell carcinoma
(RCC) is a specific and important clinical problem. Advanced laboratory techniques helped to identify the
potent role of membrane receptors for growth factors and cascade of triggered molecular reactions that lead
to phenotypic changes from normal to neoplastic, uncontrolled proliferation and angiogenesis. Due to its
high metabolic activity, formation of new blood vessels within the tumor burden is crucial for the development
of renal cell carcinoma. Main points for signals transduction in angiogenesis are VEGF-dependent and PDGF-
-dependent pathways. Agents targeting certain elements of these chain reactions linking cell membrane
and the nucleus are effective in therapy of patients with metastatic renal cell carcinoma.
Keywords: renal cancerangiogenesisbevacizumab